Touchlight Showcases Synthetic DNA Platforms and AI-Driven Bioprocessing Strategy

Touchlight spent the week spotlighting its synthetic DNA platforms as alternatives to traditional plasmid DNA across multiple advanced-therapy use cases. The company’s updates emphasized technical advantages intended to address bottlenecks in gene therapy, gene editing, and non-viral delivery.

Several posts focused on Touchlight’s doggybone DNA, or dbDNA, highlighting comparative data that suggest smaller delivery complexes and higher, more durable in vivo protein expression versus plasmid DNA. The data, generated with Sartorius Polyplus non-viral reagents, point to potential performance benefits in tissues such as lung, spleen, and muscle.

Touchlight also underscored manufacturing constraints in recombinant AAV gene therapy, noting that plasmid backbones can contribute to empty capsid formation and lower vector quality. The company positioned its bacteria-free dbDNA platform as a potential solution to improve rAAV upstream production and overall vector consistency.

In parallel, management promoted a broader strategic shift toward cell-free DNA formats for cell and gene therapy manufacturing. LinkedIn content highlighted dbDNA’s rapid production, straightforward scale-up, and reduced risk of bacterial impurities, framing the platform as suitable for gene therapies, mRNA vaccines, and cell-based treatments.

Beyond dbDNA, Touchlight showcased its Megabulb DNA, or mbDNA, suite, including several circular constructs designed for gene-editing workflows. The company claims these formats can support higher homology-directed repair efficiency, better cell viability, and larger payload capacity, aiming to serve complex synthetic biology and therapeutic programs.

Touchlight further drew attention to a blog exploring how artificial intelligence could reshape bioprocessing in genetic medicines. The company framed AI-enabled process optimization, predictive modeling, and enhanced quality control as potential tools to boost scalability and differentiation in synthetic DNA manufacturing.

Across these communications, Touchlight concentrated on scientific positioning rather than disclosing revenue metrics, capacity details, or specific partnership agreements. The week’s news collectively suggests an ongoing effort to build credibility around its DNA formats, which could influence future demand, collaborations, and the company’s standing in the gene therapy and gene-editing supply chain.